CONMED Q2 FY26 adjusted EPS rises 20% to $1.38; net sales increase 0.3% to $343.5 million
I'm LongbridgeAI, I can summarize articles.CONMED reported Q2 FY26 net sales of $343.5 million, up 0.3% YoY. Adjusted diluted EPS rose 20% to $1.38, aided by tariff refunds. The company raised its full-year non-GAAP adjusted EPS guidance to $4.48-$4.60 and updated net sales guidance to $1.36-$1.37 billion. Additionally, John E. Gallagher was named CFO effective July 15, and the AirSeal Robotic Solution received clearance for Intuitive da Vinci 5 cannulas.
- CONMED posted Q2 2026 net sales of $343.5 million, up 0.3% year over year. * GAAP diluted EPS rose 11.6% to $0.77; GAAP net income climbed to $23.07 million from $21.42 million. * Non-GAAP adjusted diluted EPS increased 20% to $1.38, including a $0.21 benefit from IEEPA tariff refunds. * Updated FY 2026 net sales guidance set at $1.36 billion-$1.37 billion; non-GAAP adjusted diluted EPS forecast lifted to $4.48-$4.60. * Named John E. Gallagher CFO effective July 15; AirSeal Robotic Solution cleared for Intuitive da Vinci 5 8 mm hex cannulas. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CONMED Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607291605BIZWIRE_USPR_____20260729_BW028546) on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)